Assertio Therapeutics Stock Net Income
| ASRT Stock | USD 12.26 0.15 1.24% |
As of the 28th of January, Assertio Therapeutics shows the Mean Deviation of 2.57, downside deviation of 3.37, and Risk Adjusted Performance of 0.0242. Assertio Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Assertio Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.1833 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -19.4 M | -20.4 M | |
| Net Income Applicable To Common Shares | 98.7 M | 103.6 M | |
| Net Loss | -19.4 M | -20.4 M | |
| Net Loss | (3.06) | (3.21) | |
| Net Income Per E B T | 0.90 | 1.24 |
Assertio | Net Income | Build AI portfolio with Assertio Stock |
Latest Assertio Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Assertio Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Assertio Therapeutics financial statement analysis. It represents the amount of money remaining after all of Assertio Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Assertio Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assertio Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (21.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Assertio Net Income Regression Statistics
| Arithmetic Mean | (32,050,997) | |
| Geometric Mean | 36,558,079 | |
| Coefficient Of Variation | (352.79) | |
| Mean Deviation | 77,157,884 | |
| Median | (20,394,045) | |
| Standard Deviation | 113,073,590 | |
| Sample Variance | 12785.6T | |
| Range | 463.7M | |
| R-Value | (0.27) | |
| Mean Square Error | 12636.3T | |
| R-Squared | 0.07 | |
| Significance | 0.29 | |
| Slope | (6,068,627) | |
| Total Sum of Squares | 204570.2T |
Assertio Net Income History
Other Fundumenentals of Assertio Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Assertio Therapeutics Net Income component correlations
Assertio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Assertio Therapeutics is extremely important. It helps to project a fair market value of Assertio Stock properly, considering its historical fundamentals such as Net Income. Since Assertio Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Assertio Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Assertio Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assertio Therapeutics. If investors know Assertio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assertio Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.19) | Earnings Share (4.50) | Revenue Per Share | Quarterly Revenue Growth 0.694 | Return On Assets |
The market value of Assertio Therapeutics is measured differently than its book value, which is the value of Assertio that is recorded on the company's balance sheet. Investors also form their own opinion of Assertio Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Assertio Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assertio Therapeutics' market value can be influenced by many factors that don't directly affect Assertio Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assertio Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assertio Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assertio Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Assertio Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Assertio Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Assertio Therapeutics.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Assertio Therapeutics on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Assertio Therapeutics or generate 0.0% return on investment in Assertio Therapeutics over 90 days. Assertio Therapeutics is related to or competes with INC Research, Nutriband, XBiotech, Fortress Biotech, Acrivon Therapeutics, Tscan Therapeutics, and Pulmonx Corp. Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and... More
Assertio Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Assertio Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Assertio Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.37 | |||
| Information Ratio | 0.001 | |||
| Maximum Drawdown | 24.64 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.07 |
Assertio Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assertio Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Assertio Therapeutics' standard deviation. In reality, there are many statistical measures that can use Assertio Therapeutics historical prices to predict the future Assertio Therapeutics' volatility.| Risk Adjusted Performance | 0.0242 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0012 | |||
| Treynor Ratio | 0.063 |
Assertio Therapeutics January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0242 | |||
| Market Risk Adjusted Performance | 0.073 | |||
| Mean Deviation | 2.57 | |||
| Semi Deviation | 3.16 | |||
| Downside Deviation | 3.37 | |||
| Coefficient Of Variation | 4574.13 | |||
| Standard Deviation | 3.8 | |||
| Variance | 14.47 | |||
| Information Ratio | 0.001 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0012 | |||
| Treynor Ratio | 0.063 | |||
| Maximum Drawdown | 24.64 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.07 | |||
| Downside Variance | 11.38 | |||
| Semi Variance | 9.96 | |||
| Expected Short fall | (2.82) | |||
| Skewness | 1.13 | |||
| Kurtosis | 3.76 |
Assertio Therapeutics Backtested Returns
Assertio Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Assertio Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0543, which signifies that the company had a 0.0543 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Assertio Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Assertio Therapeutics' Mean Deviation of 2.57, downside deviation of 3.37, and Risk Adjusted Performance of 0.0242 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Assertio Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.16, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Assertio Therapeutics will likely underperform. Please check Assertio Therapeutics' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Assertio Therapeutics' price patterns will revert.
Auto-correlation | 0.04 |
Virtually no predictability
Assertio Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Assertio Therapeutics time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Assertio Therapeutics price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current Assertio Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | -0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.96 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Assertio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Assertio Therapeutics reported net income of (21.58 Million). This is 106.32% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 103.78% higher than that of the company.
Assertio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assertio Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assertio Therapeutics could also be used in its relative valuation, which is a method of valuing Assertio Therapeutics by comparing valuation metrics of similar companies.Assertio Therapeutics is currently under evaluation in net income category among its peers.
Assertio Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Assertio Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Assertio Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Assertio Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Assertio Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Assertio Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Assertio Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 366.9 K | Perritt Capital Management Inc. | 2025-06-30 | 360.3 K | Ubs Group Ag | 2025-06-30 | 334.2 K | Tsp Capital Management Group/llc | 2025-06-30 | 316.9 K | Citadel Advisors Llc | 2025-06-30 | 288.8 K | Amvescap Plc. | 2025-06-30 | 270.7 K | Northern Trust Corp | 2025-06-30 | 227.2 K | Bridgeway Capital Management, Llc | 2025-06-30 | 223.4 K | Empowered Funds, Llc | 2025-06-30 | 223.4 K | Nantahala Capital Management, Llc | 2025-06-30 | 8.8 M | Vanguard Group Inc | 2025-06-30 | 4.4 M |
Assertio Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0417 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 25.17 M | ||||
| Shares Outstanding | 6.42 M | ||||
| Shares Owned By Insiders | 2.49 % | ||||
| Shares Owned By Institutions | 27.40 % | ||||
| Number Of Shares Shorted | 285.11 K | ||||
| Price To Earning | 4.93 X | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 0.57 X | ||||
| Revenue | 124.96 M | ||||
| Gross Profit | 89.93 M | ||||
| EBITDA | 5.15 M | ||||
| Net Income | (21.58 M) | ||||
| Cash And Equivalents | 52.26 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 40.27 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 1.00 X | ||||
| Book Value Per Share | 16.49 X | ||||
| Cash Flow From Operations | 26.41 M | ||||
| Short Ratio | 5.67 X | ||||
| Earnings Per Share | (4.50) X | ||||
| Price To Earnings To Growth | 1.50 X | ||||
| Target Price | 37.44 | ||||
| Number Of Employees | 58 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 78.67 M | ||||
| Total Asset | 284.73 M | ||||
| Retained Earnings | (673.12 M) | ||||
| Working Capital | 87.86 M | ||||
| Current Asset | 5.15 M | ||||
| Current Liabilities | 492.4 K | ||||
| Net Asset | 284.73 M |
About Assertio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Assertio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assertio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assertio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.